Lipoproteína(a)
Grupo Argentino Estudio Lipoproteína (a)
.png)
Novedades Junio 2026
Med Sci (Basel). 2026 Apr 30;14(2):227. doi: 10.3390/medsci14020227.
Autores:
Mesud Jamaković 1 , Armin Šljivo 2 , Azra Durak-Nalbantić 1 , Farid Ljuca 3 , Mugdim Bajrić 4 , Behija Hukeljić-Berberović 2
Conclusión: Elevated Lp(a) is associated with increased coronary artery disease severity and higher mid-term MACE risk after AMI.
JAAPA. 2026 Jun 1;39(6):16-21. doi: 10.1097/01.JAA.0000000000000361. Epub 2026 May 26.
Autores:
Nolan Crain 1
J Lipid Res. 2026 May;67(5):101032. doi: 10.1016/j.jlr.2026.101032. Epub 2026 Apr 2.
Autores:
Munkhtuya Myagmarsuren 1 , Hayley G Law 1 , Wei Zhang 1 , Heejung Bang 2 , Lauren M Bishop 3 , Tong Shen 3 , Oliver Fiehn 3 , Kristina S Petersen 4 , Lars Berglund 1 , Byambaa Enkhmaa 5
High Blood Press Cardiovasc Prev. 2026 May;33(3):337-349. doi: 10.1007/s40292-026-00783-8. Epub 2026 Mar 18.
Autores:
Giulia Nardoianni # 1 , Giuliano Tocci # 2 3 4 , Barbara Pala 1 5 , Marco Russo 1 , Giovanni Marco Dutti 1 6 , Federica Fogacci 7 , Arrigo F G Cicero 7 8 , Massimo Volpe 1 6 , Emanuele Barbato 1
Conclusión: In our population, Lp(a) levels were not associated with either office or out-of-office BP values, irrespective of antihypertensive treatment status. The role of Lp(a) in hypertension warrants further investigation.
J Am Coll Cardiol. 2026 May 26;87(20):2785-2803. doi: 10.1016/j.jacc.2026.01.076. Epub 2026 Mar 18.
Autores:
Raysha Farah 1 , Min Seo Kim 2 , Buu Truong 2 , Yang Sui 2 , So Mi Jemma Cho 3 , Sarah Margaret Urbut 2 , Aniruddh Patel 2 , Paul M Ridker 4 , Pradeep Natarajan 2 , Akl C Fahed 5
Conclusión: CAD PRS, LDL-C, hsCRP, and Lp(a) show independent age- and sex-specific associations with CAD. Measuring all 4 biomarkers may improve midlife CAD risk prediction for both male and female patients.
J Am Coll Cardiol. 2026 May 26;87(20):2864-2872. doi: 10.1016/j.jacc.2026.02.5067. Epub 2026 Mar 16.
Autores:
Harpreet S Bhatia 1 , Yihang Fan 2 , Gourisree Dharmavaram 3 , Alexander C Razavi 4 , Michael Y Tsai 5 , Mattheus Ramsis 3 , Ehtisham Mahmud 3 , Michael Wilkinson 3 , Pam Taub 3 , Khurram Nasir 6 , Michael J Blaha 7 , Nathan D Wong 2
Conclusión: Elevated Lp(a) is associated with higher relative risk across CAC strata, including CAC of 0. Among individuals with CAC of 0, absolute event rates remain low even when Lp(a) is elevated. CAC scoring remains a powerful tool for risk assessment among individuals with elevated Lp(a).
BMC Cardiovasc Disord. 2026 Apr 16;26(1):460. doi: 10.1186/s12872-026-05847-0.
Autores:
Tao Sun 1 , Wenhao Zhang 2 , Pingyan Fei 1 , Yueping Shi 1 , Xuelian Zhang 3
Conclusión: When HCY is elevated, patients with increased Lp(a) experience amplified risk of recurrent cardiovascular events. This association shifts when HCY is at low levels. Future efforts should emphasize combined assessment of Lp(a) and HCY and explore targeted intervention strategies to reduce residual cardiovascular risk.
Prog Lipid Res. 2026 Jun:101:101375. doi: 10.1016/j.plipres.2025.101375. Epub 2025 Dec 24.
Autores:
Ivan Antipenko 1 , Anna Stepanova 2 , Maxim Shkurnikov 3 , Kianoush Jeiran 4 , Ancha Baranova 5 , Alexander Tonevitsky 6
J Clin Hypertens (Greenwich). 2026 Jun;28(6):e70309. doi: 10.1111/jch.70309.
Autores:
Bibombe P Mwipatayi 1 , James Dodd 2 , Revathy Carnagarin 3 , Trevor A Mori 4 , Jonathan Golledge 5 6 , Sally Burrows 7 , Gerald F Watts 4 8 , Osamu Iida 9 , Markus P Schlaich 3 10
Curr Atheroscler Rep. 2026 Jun 3;28(1):59. doi: 10.1007/s11883-026-01419-x.
Autores:
Khalil Anchouche 1 , Nicholas Koran 2 , George Thanassoulis 3 4
Diabetes Metab Syndr. 2026 Apr;20(4):103422. doi: 10.1016/j.dsx.2026.103422. Epub 2026 Apr 25.
Autores:
Sudipta Chattopadhyay 1 , Jason Sangha 2 , Thozhukat Sathyapalan 3
Conclusión: Lp(a) is inversely related to T2DM risk only in subjects with severe prediabetes. Direct association between Lp(a) and cardiovascular outcomes is seen only in subjects without prediabetes.
J Clin Lipidol. 2026 Jun;20(6):1054-1064. doi: 10.1016/j.jacl.2026.03.019. Epub 2026 Apr 1.
Autores:
Martin D Mulligan 1 , Rahul S Gandhi 2 , Rishabh Vishwakarma 3 , Romit Bhattacharya 4
Conclusión: No statistically significant differences in Lp(a) reduction were observed between currently available PCSK9-targeting medications. Agent selection may reasonably be based on non-efficacy factors, including administration frequency, cost, and patient preference.
Mol Ther. 2026 Jun 3;34(6):3334-3352. doi: 10.1016/j.ymthe.2026.02.049. Epub 2026 Mar 3.
Autores:
Marcel A Chuecos 1 , So Hyun Park 2 , Madhvi M Bhakta 3 , Usosa Too-Chiobi 3 , Daniel Betancourth 2 , Mingming Cao 2 , Marco De Giorgi 3 , Christopher J Walkey 3 , Anjana Tiwari 4 , Biana Godin 5 , Julia M Assini 6 , Donna J Palmer 7 , Philip Ng 7 , Michael B Boffa 6 , Marlys L Koschinsky 8 , Gang Bao 2 , William R Lagor 9
Cardiovasc J Afr. 2024 Nov-Dec;35(4):246-250. doi: 10.5830/CVJA-2023-038. Epub 2023 Aug 25.
Autores:
Songül Usalp 1 , Emine Altuntaş 2 , Bayram Bağırtan 2 , Kanber Ö Karabay 2
Conclusión: Lp(a) level was found to be a higher and a possible independent risk factor in young patients who presented with STEMI for the first time, compared to the middle-aged patient group. Lp(a) is a highly atherogenic molecule and it has been associated with stroke, heart failure, aortic stenosis, as well as coronary artery disease. Measurement of Lp(a) levels may be recommended in young patients with high cardiovascular risk.
Nat Cardiovasc Res. 2026 Jun;5(6):565-571. doi: 10.1038/s44161-026-00821-7. Epub 2026 May 29.
Autores:
Mark Atallah 1 , Nadim Nasrallah 1 , Tarek Harb 1 , Ines Valenta 2 , Thomas H Schindler 2 , Amelia S Wallace 3 , Sotirios Tsimikas 4 , Gary Gerstenblith 1 , Thorsten M Leucker 5
Int J Cardiol. 2026 Sep 15:459:134588. doi: 10.1016/j.ijcard.2026.134588. Epub 2026 May 26.
Autores:
Ahmed K Mahmoud 1 , Hesham Sheashaa 2 , Michael Killian 3 , Kamal Awad 4 , Ramzi Ibrahim 4 , Alaa Mahmoud 5 , Juan Farina 4 , Mahmoud Abdelnabi 4 , Ibrahim Kamel 6 , Benjamin Horn 7 , David Simper 4 , Steven J Lester 4 , Chadi Ayoub 4 , Reza Arsanjani 4
Conclusión: In patients with elevated Lp(a), GLP-1RA therapy was associated with substantial reductions in mortality and cardiovascular events. These findings suggest potential cardioprotective effects of GLP-1RAs in a high-risk population with limited therapeutic options and support further prospective evaluation.
Atherosclerosis. 2026 Jun:417:120759. doi: 10.1016/j.atherosclerosis.2026.120759. Epub 2026 Apr 25.
Autores:
Karin Littmann 1 , Daniel Eriksson Hogling 2 , Mustafa Suhel 2 , Kamilla Juhlin 3 , Pinar Kara 4 , Matteo Bottai 4 , Niclas Svedberg 5 , Anna M Nordenskjöld 6 , Mattias Ekström 7 , Linda Mellbin 8 , Per Grimfjärd 9 , David Erlinge 3 , Emil Hagström 10 , Jonas Brinck 2
Conclusión: Cascade screening for elevated Lp(a) in relatives of patients with CAD is feasible in a real-world setting. Screening was up to five times more effective when initiated from patients with elevated Lp(a) than with low.
Atherosclerosis. 2026 Jun:417:120754. doi: 10.1016/j.atherosclerosis.2026.120754. Epub 2026 Apr 23.
Autores:
Johan Skov Bundgaard 1 , Søren Albertsen Rand 2 , Stefan Stender 3 , Jesper Hastrup Svendsen 4 , Pia Rengtved Lundegaard 5 , Christian Erikstrup 6 , Gustav Ahlberg 5 , Ruth Frikke-Schmidt 3 , Lars Dyrskjøt 7 , Ole Halfdan Larsen 7 , Henning Bundgaard 4 , Jonas Ghouse 8
Conclusión: In this large primary prevention cohort, we found that IL-6 modifies Lp(a)-associated cardiovascular risk.
J Clin Invest. 2026 Apr 16;136(12):e204287. doi: 10.1172/JCI204287. eCollection 2026 Jun 15.
Autores:
Sascha N Goonewardena 1 2 , Shanshan Yao 1 , Tomasz Jurga 3 , Lanyue Zhang 4 , Donald Lloyd-Jones 5 , Dilna Damodaran 1 , Bharat Thyagarajan 6 , David R Jacobs Jr 7 , Supriya Shore 1 , Eric J Brandt 1 8 , Clary Clish 9 , Kahraman Tanriverdi 10 , Jane E Freedman 10 , Chirag J Patel 11 , Mark A Sarzynski 12 , Brian T Emmer 13 , John T Wilkins 14 , Ron Do 15 , Vera Bittner 16 , Ravi V Shah 10 , Marios K Georgakis 4 17 18 , Robert S Rosenson 19 , Venkatesh L Murthy 1
Circ Genom Precis Med. 2026 Jun;19(3):e005494. doi: 10.1161/CIRCGEN.125.005494. Epub 2026 Apr 10.
Autores:
Jianfeng Xu 1 2 , Zhuqing Shi 1 , Sumeet A Khetarpal 3 , Ashley J Mulford 4 , Osama Siddiqui 5 , Huy Tran 1 , Jun Wei 1 , Annabelle Ashworth 1 , S Lilly Zheng 1 , David Duggan 6 , Brian T Helfand 1 2 , Henry M Dunnenberger 7 , Peter J Hulick 7 , David J Davidson 5 , Amit V Khera 8 9 10 , Aniruddh P Patel 9 11 12 13 , Alan R Sanders 2 4 , Arman Qamar 5
Conclusión: GenProbCAD, a novel integrated genetic risk tool combining monogenic PVs, polygenic risk scores for CAD, and PRSLp(a), improves identification of individuals at high genetic risk for CAD across diverse populations.
High Blood Press Cardiovasc Prev. 2026 Jul;33(4):425-437. doi: 10.1007/s40292-026-00781-w. Epub 2026 Mar 18.
Autores:
Chiara Tognola 1 , Davide Paolo Bernasconi 2 3 , Paola Rebora 2 4 , Rita Cristina Myriam Intravaia 5 , Costantino Mancusi 6 , Valeria Visco 7 , Arturo Cesaro 8 9 , Enrica Golia 8 9 , Fucile Ilaria 6 , Piera Merlini 1 , Maddalena Ardissino 10 11 , Elvira Inglese 12 , Romano Danesi 12 13 , Fabrizio Oliva 14 , Anita Andreano 15 , Magda Rognoni 15 , Antonio Russo 16 , Paolo Calabrò 8 9 , Nicola De Luca 6 , Cristina Giannattasio 1 17 , Alessandro Maloberti 18 19
Conclusión: In this primary prevention cohort, elevated Lp(a) levels were not associated with significant structural damage to the heart, carotid arteries, or increased aortic stiffness and were not associated with CV events and all-cause mortality.
Sleep. 2026 Jun 15;49(6):zsag062. doi: 10.1093/sleep/zsag062.
Autores:
Wen Hao 1 , Yuyao Qiu 2 , Zekun Zhang 1 , Bin Wang 3 , Wei Gong 4 , Wen Zheng 1 , Hui Wang 5 , Lei Xu 5 , Shaoping Nie 1 6 , Xiao Wang 7
Conclusión: OSA was associated with a continuously increased cardiovascular risk and a higher prevalence of HRP features as Lp(a) levels rose. Lp(a) may help identify ACS patients at higher cardiovascular risk, in whom the efficacy of OSA treatment should be further investigated.